Home » Authors » Kim Coghill

Articles by Kim Coghill

Santarus Gets FDA Approval For Rapinex Powder Version

June 17, 2004

Axonyx Begins Second Pivotal Phenserine Trial In Alzheimer's

June 17, 2004

InterMune Begins Phase III Trial Of Once-Daily Infergen

June 16, 2004

InterMune Inc. started a Phase III trial to evaluate the once-daily use of Infergen in combination with ribavirin for patients chronically infected with hepatitis C virus who have failed to respond to a previous course of therapy with pegylated interferon alfa-2 plus ribavirin. (BioWorld Today)

InterMune Begins Phase III Trial Of Once-Daily Infergen

June 16, 2004

InterMune Inc. started a Phase III trial to evaluate the once-daily use of Infergen in combination with ribavirin for patients chronically infected with hepatitis C virus who have failed to respond to a previous course of therapy with pegylated interferon alfa-2 plus ribavirin. (BioWorld Today)

Alexion, P&G Get FDA Clearance On Pexelizumab Phase III Design

June 15, 2004

OSI Reports Anticipated Negative Results In Aptosyn Phase III Trial

June 15, 2004

OSI Reports Anticipated Negative Results In Aptosyn Phase III Trial

June 15, 2004

Alexion, P&G Get FDA Clearance On Pexelizumab Phase III Design

June 15, 2004

Momentum Growing For Effort To Legalize Drug Importation

June 14, 2004

NCI, CMS Begin Initiative To Improve Information On Cancer

June 14, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.